VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma

This phase II trial tests adding VSV-IFNβ-NIS to standard of care ipilimumab and nivolumab for the treatment of clear cell renal cell carcinoma that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic). A virus modified in the laboratory, such as VSV-IFNβ-NIS, may be able to kill tumor cells without damaging normal cells. Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system a

Trial Details

NCT ID

NCT07510334

Phase

PHASE2

Sponsor

Mayo Clinic

Status

RECRUITING

Cancer Type

Kidney Cancer

Interventions

Biopsy Procedure
Biospecimen Collection
Computed Tomography
Ipilimumab
Nivolumab
Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter

Locations (sample)

Rochester, Minnesota, United States|44.02163,-92.4699

Key Eligibility Criteria

Age ≥ 18 years
Disease Characteristics:
Histological confirmation of advanced (not amenable to curative surgery or radiation therapy) or metastatic \[American Joint Committee on Cancer (A…
Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Kidney Cancer Trials on Trialify →